RT Book, Section
A1 Shaw, Leslee J.
A1 Taqueti, Viviany R.
A1 Wenger,  Nanette K.
A2 Fuster, Valentin
A2 Narula, Jagat
A2 Vaishnava, Prashant
A2 Leon, Martin B.
A2 Callans, David J.
A2 Rumsfeld, John S.
A2 Poppas, Athena
SR Print(0)
ID 1202453805
T1 Women and Ischemic Heart Disease
T2 Fuster and Hurst's The Heart, 15e
YR 2022
FD 2022
PB McGraw-Hill Education
PP New York, NY
SN 9781264257560
LK accesscardiology.mhmedical.com/content.aspx?aid=1202453805
RD 2024/04/19
AB Chapter  SummaryThis  chapter  highlights  the  evidence  on  sex  differences  in  the  pathophysiology  and  clinical  presentations  of  ischemic  heart  disease  (IHD),  and  identifies  significant  disparities  in  primary  prevention  and  both  stable  and  acute  management  strategies  contributing  to  the  often-reported  high  adverse  risk  for  women.  Throughout  the  20th  century,  atherosclerotic  cardiovascular  disease  (ASCVD)  was  viewed  as  predominantly  a  disease  of  older-aged  men,  and  little  information  was  available  regarding  its  impact  on  women.  Recent  decades  have  witnessed  emerging  attention  to  ASCVD  in  women,  with  consequent  research  hypotheses  focused  on  data  specific  to  women.  Today,  there  exists  growing  evidence  on  sex  differences  in  prevention,  presentation,  diagnostic  evaluation,  management,  and  clinical  outcomes  of  women  compared  with  men  with  suspected  and  known  IHD.  The  gamut  of  cultural,  social,  and  financial  differences  among  women  and  men  profoundly  impact  prompt  diagnosis,  clinical  management,  and  outcomes  of  at-risk  women.  Goals  for  reducing  ASCVD  risk  tailored  to  women  remain  underexplored.  The  role  of  biology,  clinical  and  population  needs  of  women,  and  the  socioeconomic  disparities  of  females  remain  sizeable  hurdles  to  effecting  changes  to  the  large  population  of  young  to  older  women  at  risk  for  ASCVD  (see  Fuster  and  Hurst’s  Central  Illustration).